End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- AUD | -.--% | -.--% | -.--% |
19/04 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
15/04 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Sales 2024 * | 1.6M 1.05M 87.26M | Sales 2025 * | 6.4M 4.18M 349M | Capitalization | 46.93M 30.69M 2.56B |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.23M -436M | Net income 2025 * | -5M -3.27M -273M | EV / Sales 2024 * | 24.9 x |
Net cash position 2024 * | 7.1M 4.64M 387M | Net cash position 2025 * | 9.4M 6.15M 513M | EV / Sales 2025 * | 5.86 x |
P/E ratio 2024 * |
-5.48
x | P/E ratio 2025 * |
-11.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.68% |
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 07/16/07 |
Mark Edwards
DFI | Director of Finance/CFO | - | 02/22/02 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 20/21/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | 29/11 | |
Philip Powell
BRD | Director/Board Member | 65 | 18/19/18 |
Geoff Cumming
BRD | Director/Board Member | - | 28/20/28 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+46.34% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- IIQ Stock
- BD1 Stock